Biotest Adopts Veeva Vault eTMF for Real-Time Visibility into Study Documents and Processes
Veeva Systems (NYSE: VEEV) today announced that Biotest, a German biopharmaceutical company specializing in plasma proteins, implemented Veeva Vault eTMF to achieve greater visibility across its European trials. Vault eTMF enables Biotest to manage all study documents and activities in real-time as the TMF is generated. Now the company can maintain a constant state of inspection readiness and give teams a complete view into TMF status for faster study execution.
“We are increasing our efficiency and inspection readiness due to improved accessibility of trial documents with Veeva Vault eTMF,” said Daniela Zipp, head of operations, clinical systems, and data management at Biotest. “The local Veeva team in Germany provided tremendous support to get us up and running quickly. We now have the foundation and metrics in place to improve our study processes and oversight.”
Vault eTMF enables active TMF management so Biotest can manage study processes and documents in one system, in real-time, as they are executed. Advanced reporting and dashboards provide insights into document and process status at all times. Full visibility into TMF completeness allows sponsors, CROs, and sites to work better together during trials and accelerate execution.
“Companies are modernizing clinical operations to drive more efficient trials and speed drug development,” said Rik Van Mol, vice president of Veeva Development Cloud in Europe. “Veeva Vault eTMF gives Biotest greater transparency into TMF quality to improve compliance and collaboration throughout the course of their study execution.”
Veeva Vault eTMF is part of the Veeva Vault Clinical Suite, the industry’s first cloud platform that includes CDMS, CTMS, eTMF, and study start-up to unify clinical data management and clinical operations. Veeva’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes. For more information, visit veeva.com/Clinical.
Additional Information
For more on Veeva Vault eTMF, visit: veeva.com/eTMF
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors, and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Learn more at www.biotest.com.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005381/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veridas Identity Fraud Solutions Now Available on AWS Marketplace21.8.2025 19:05:00 EEST | Press release
Veridas, a global leader in identity verification and biometric solutions, today announced that its Identity Verification (IDV) platformis now available on Amazon Web Services (AWS) Marketplace. This launch puts the full power of Veridas’ fraud prevention and identity verification capabilities in the hands of millions of AWS customers worldwide, making secure digital trust only a click away. As identity fraud rises exponentially — with threats from synthetic identities, deepfakes, and injection attacks — Veridas delivers a cloud-native solution combining facial biometrics, AI-driven document authentication, and certified liveness detection. The platform shields enterprises from fraud while enabling seamless onboarding in seconds. “Live since 2017, our IDV platform already protects more than 300 clients in 25 countries against advanced fraud such as deepfakes and injection attacks, with 100% proprietary technology, global coverage, and international compliance,” said Eduardo Azanza, CEO
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™21.8.2025 18:21:00 EEST | Press release
Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud to be supporting Steel Therapeutics at this key stage of their development journey,” said Steve Mason, Co-COO at Altasciences. “Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.” Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach b
Media alert | Masdar receives ‘AA-’ credit rating with stable outlook by S&P Global Ratings in further recognition of the financial strength of the business21.8.2025 16:55:00 EEST | Press release
Masdar has been assigned an ‘AA-’ credit rating with a stable outlook by S&P Global Ratings, reinforcing its position as a global clean energy leader. This new rating reflects Masdar's diversified global position, strong growth prospects, and disciplined financial policies, including the allocation of green bond proceeds to finance the construction of new projects. With top credit ratings now secured from Moody’s (A1), Fitch (AA-) and S&P (AA-), Masdar continues to be recognized as one of the most financially robust renewable energy companies worldwide. This enables the Company to continue to drive responsible expansion and deliver inclusive progress across key international markets. The rating is also underpinned by the strong support of the Company's three shareholders - Abu Dhabi National Oil Company (ADNOC), Mubadala Investment Company, and Abu Dhabi National Energy Company PJSC (TAQA) - as well as the Government of Abu Dhabi. View source version on businesswire.com: https://www.bu
Andersen Consulting Expands Presence Through Collaboration with Ignis21.8.2025 16:30:00 EEST | Press release
Andersen Consulting adds depth to its strategy capabilities with collaborating firm Ignis, a leading media agency, reinforcing the organization’s commitment to delivering seamless solutions to clients globally. Founded in Buenos Aires, Ignis has earned a reputation for helping organizations build and achieve their brand objectives. With expertise in marketing communications strategy, market research, media planning and buying, and digital marketing, the firm works with companies in industries such as banking, insurance, and food and beverage across Latin America to drive brand growth, customer engagement, and measurable business results. “We’ve built Ignis with a spirit of entrepreneurship and bold thinking, and this collaboration enhances the global reach and resources to continue scaling that vision,” said Alejandro Terzi, chairman and founder of Ignis. “It opens new doors for innovation, fuels our ability to take on more ambitious challenges, and ultimately, allows us to deliver eve
Verb Technology Announces $780 Million in Treasury Assets to Advance its TON Treasury Strategy21.8.2025 16:20:00 EEST | Press release
Verb Technology Company, Inc. (Nasdaq: VERB) (to be renamed Ton Strategy Company) (the “Company”) today announced treasury assets exceeding $780 million, including $713 million1 of Toncoin ($TON), the native cryptocurrency of The Open Network (“TON”) Blockchain, and $67 million of cash. This is an important milestone in the Company’s implementation of its previously announced $TON treasury strategy. Today’s news follows the Company’s August 8 closing of a $558 million private placement joined by more than 110 institutional and crypto-native investors. The Company used the majority of proceeds from the private placement to acquire $TON as its primary treasury reserve asset. "Crossing $780 million in assets just days after our private placement reflects the conviction behind $TON,” said Manuel Stotz, Executive Chairman of the Company. “This is more than building a balance sheet; it’s about contributing to the security of TON blockchain – where participants can build, transact, and benefi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom